News
Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference
Salt Lake City, Utah--(February 8, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that Brian M. Strem, Ph.D, President and CEO of Kiora, will present a Company overview at the BIO CEO & Investor Conference on...
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
Salt Lake City, Utah--(February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman,...
Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference
Salt Lake City, Utah--(January 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian Strem, Ph.D., President and Chief Executive Officer, will provide an outlook for the...
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
Salt Lake City, Utah--(December 15, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced the appointment of David Hollander, MD, MBA, to its Board of Directors. Dr. Hollander, who currently serves as the Chief Research and...
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
Salt Lake City, Utah--(December 14, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients...
Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
SALT LAKE CITY, Nov. 15, 2021 -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities. "We recently...
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy
SALT LAKE CITY, Nov. 08, 2021 -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number...